Recombinant interferon α The value of 2B in the treatment of hand foot mouth disease
重组干扰素α2b治疗手足口病的价值

摘要

目的 探究临床治疗手足口病时应用α2b（重组干扰素）的价值。方法研究共有受试者60例，均选取自我院感染科，选取时间为2021年2月到2022年3月，将所有受试对象进行随机分组，分成研究组、对照组，每组平均30人，组内应用不同的治疗方法，比对最终疗效和病人疼痛指数变化。结果研究组手足口病人治疗显效和有效例数之和为28例，总有效率明显更高，P＜0.05；治疗前，组间口腔疼痛程度差异小；治疗后，2组疼痛程度评分均降低，但研究组评分明显更低，研究数据排除治疗前和治疗后1天，其余数值对比均为P＜0.05；治疗后，2组手足口病患儿症状均有所好转，研究组内小儿高热、疱疹和皮疹等症状消退时间更快，总住院时长更短，P＜0.05。结论 针对手足口病α2b（重组干扰素）的临床药效显著，治疗后患儿疼痛指数逐渐降低，适合积极推广。

Abstract

Objective: To explore the clinical application in the treatment of hand, foot and mouth disease α Value of 2B (recombinant interferon).
Methods: a total of 60 subjects were selected from the Department of nosocomial infection from February 2021 to March 2022. All subjects were randomly divided into study group and control group, with an average of 30 people in each group. Different treatment methods were used in the group to compare the final therapeutic effect and the change of patient pain index.
Results: in the study group, the total effective rate was significantly higher (P; Before treatment, there was little difference in the degree of oral pain between groups; After treatment, the pain scores of the two groups decreased, but the scores of the study group were significantly lower. The study data excluded the pre-treatment and 1 day after treatment, and the other values were compared (P < 0.05).；After treatment, the symptoms of both children with HFMD improved. In the study group, symptoms with high fever, herpes and rash subsided faster and the total hospitalization was shorter, P <0.05.
Conclusion  : for HFMD α The clinical efficacy of 2B (recombinant interferon) is significant, and the pain index of children gradually decreases after treatment, which is suitable for active promotion.